[November 08, 2017] |
|
Cervical Cancer Market Spotlight Report 2017 - Research and Markets
The "Market
Spotlight: Cervical Cancer" report has been added to Research
and Markets' offering.
This Market Spotlight report covers the cervical cancer market,
comprising key pipeline and marketed drugs, clinical trials, upcoming
events, patent information, a 10-year disease prevalence forecast, and
licensing and acquisition deals, as well as presenting drug-specific
revenue forecasts.
Key Takeaways
-
The author estimates that in 2016, there were 556,200 incident cases
of cervical cancer in females worldwide, and expects that number to
increase to 609,500 incident cases by 2025.
-
Incidence cases are highest in Asia, and lowest in the Oceania region.
Roche's Avastin (bevacizumab) and Amgen's Mvasi (bevacizumab), which
target vascular endothelial growth factor; Novartis's Hycamtin
(topotecan hydrochloride), a topoisomerase I inhibitor; and Pinnacle's
Photofrin (porfmer sodium), a photodynamic therapy, are the only
marketed drugs available for cervical cancer. The majority of the
marketed drugs are administered via the intravenous route.
-
Therapies in mid-to-late-stage developent for cervical cancer focus
on a variety of targets. The majority of the drugs in mid-tolate-stage
development for cervical cancer are administered via the intravenous
route, with the remainder being intramuscular, intranasal,
subcutaneous, and oral.
-
High-impact upcoming events for drugs in the cervical cancer space
include topline Phase II and Phase III trial results. Licensing and
asset acquisition activity involving cervical cancer drugs has been
weak during 2012-17, with only 11 deals over this time period. The
$727.5m license agreement between Inovio and MedImmune for the
exclusive rights to develop and market Inovio's INO-3112 was the
largest deal during 2012-17.
-
The clinical trials distribution across Phase I-IV indicates that the
majority of trials for cervical cancer have been in early and
midphases of development, with 95% of trials in Phase I-II, and only
5% in Phase III-IV.
-
The US has a substantial lead in the number of cervical cancer
clinical trials globally. The UK leads the major EU markets, while
South Korea has the top spot in Asia.
-
Clinical trial activity in the cervical cancer space is dominated by
ongoing trials. AstraZeneca and Roche have the highest number of
ongoing clinical trials for cervical cancer, with 11 and eight ongoing
trials, respectively.
-
AstraZeneca leads industry sponsors with the highest number of
clinical trials for cervical cancer, followed by Roche.
Key Topics Covered:
1 Key Takeaways
2 Disease Background
3 Treatment
4 Epidemiology
5 Marketed Drugs
6 Pipeline Drugs
7 Key Upcoming Events
8 Licensing And Asset Acquisition Deals
9 Parent Patents
10 Revenue Opportunity
11 Clinical Trial Landscape
12 Bibliography
For more information about this report visit https://www.researchandmarkets.com/research/j7l8p7/market_spotlight
View source version on businesswire.com: http://www.businesswire.com/news/home/20171108005987/en/
[ Back To TMCnet.com's Homepage ]
|